Structure and Function of the HIV Envelope Glycoprotein as Entry Mediator, Vaccine Immunogen, and Target for Inhibitors

Advances in Pharmacology

Volumn 55, Issue , 2007, Pages 33-97

  Prabakaran, Ponraj ^a   Dimitrov, Antony S ^b   Fouts, Timothy R ^b   Dimitrov, Dimiter S ^a  

^a CCRNP   (United States)

^b UNIVERSITY OF MARYLAND BALTIMORE COUNTY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS ENVELOPE PROTEIN;

AMINO ACID SEQUENCE; CHEMISTRY; DRUG ANTAGONISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOLOGY; MEMBRANE FUSION; METABOLISM; MOLECULAR GENETICS; PHYSIOLOGY; PROTEIN BINDING; REVIEW; VIRUS INTERNALIZATION;

AIDS VACCINES; AMINO ACID SEQUENCE; HIV; HUMANS; MEMBRANE FUSION; MOLECULAR SEQUENCE DATA; PROTEIN BINDING; VIRAL ENVELOPE PROTEINS; VIRUS INTERNALIZATION;

EID: 34250667139     PISSN: 10543589     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1054-3589(07)55002-7     Document Type: Review

References (278)

1. Ahmad A., and Menezes J. Antibody-dependent cellular cytotoxicity in HIV infections. FASEB J. 10 (1996) 258-266
2. Ahmad R., Sindhu S.T., Toma E., Morisset R., Vincelette J., Menezes J., and Ahmad A. Evidence for a correlation between antibody-dependent cellular cytotoxicity-mediating anti-HIV-1 antibodies and prognostic predictors of HIV infection. J. Clin. Immunol. 21 (2001) 227-233
3. Albert J., Abrahamsson B., Nagy K., Aurelius E., Gaines H., Nystrom G., and Fenyo E.M. Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. AIDS 4 (1990) 107-112
4. Alfsen A., and Bomsel M. HIV-1 gp41 envelope residues 650-685 exposed on native virus act as a lectin to bind epithelial cell galactosyl ceramide. J. Biol. Chem. 277 (2002) 25649-25659
5. Amara R.R., Smith J.M., Staprans S.I., Montefiori D.C., Villinger F., Altman J.D., O'Neil S.P., Kozyr N.L., Xu Y., Wyatt L.S., Earl P.L., Herndon J.G., et al. Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89. 6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine. J. Virol. 76 (2002) 6138-6146
6. Arendrup M., Nielsen C., Hansen J.E., Pedersen C., Mathiesen L., and Nielsen J.O. Autologous HIV-1 neutralizing antibodies: Emergence of neutralization-resistant escape virus and subsequent development of escape virus neutralizing antibodies. J. Acquir. Immune Defic. Syndr. 5 (1992) 303-307
7. Atchison R.E., Gosling J., Monteclaro F.S., Franci C., Digilio L., Charo I.F., and Goldsmith M.A. Multiple extracellular elements of CCR5 and HIV-1 entry: Dissociation from response to chemokines. Science 274 (1996) 1924-1926
8. Baba T.W., Liska V., Hofmann-Lehmann R., Vlasak J., Xu W., Ayehunie S., Cavacini L.A., Posner M.R., Katinger H., Stiegler G., Bernacky B.J., Rizvi T.A., et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat. Med. 6 (2000) 200-206
9. Back N.K., Smit L., De Jong J.J., Keulen W., Schutten M., Goudsmit J., and Tersmette M. An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization. Virology 199 (1994) 431-438
10. Banks N.D., Kinsey N., Clements J., and Hildreth J.E. Sustained antibody-dependent cell-mediated cytotoxicity (ADCC) in SIV-infected macaques correlates with delayed progression to AIDS. AIDS Res. Hum. Retroviruses 18 (2002) 1197-1205
11. Basmaciogullari S., Pacheco B., Bour S., and Sodroski J. Specific interaction of CXCR4 with CD4 and CD8alpha: Functional analysis of the CD4/CXCR4 interaction in the context of HIV-1 envelope glycoprotein-mediated membrane fusion. Virology 353 (2006) 52-67
12. Beddows S., Schulke N., Kirschner M., Barnes K., Franti M., Michael E., Ketas T., Sanders R.W., Maddon P.J., Olson W.C., and Moore J.P. Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J. Virol. 79 (2005) 8812-8827
13. Berger E.A., Murphy P.M., and Farber J.M. Chemokine receptors as HIV-1 coreceptors: Roles in viral entry, tropism, and disease. Annu. Rev. Immunol. 17 (1999) 657-700
14. Binley J.M., Sanders R.W., Clas B., Schuelke N., Master A., Guo Y., Kajumo F., Anselma D.J., Maddon P.J., Olson W.C., and Moore J.P. A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure. J. Virol. 74 (2000) 627-643
15. Binley J.M., Wrin T., Korber B., Zwick M.B., Wang M., Chappey C., Stiegler G., Kunert R., Zolla-Pazner S., Katinger H., Petropoulos C.J., and Burton D.R. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J. Virol. 78 (2004) 13232-13252
16. Blanpain C., Lee B., Tackoen M., Puffer B., Boom A., Libert F., Sharron M., Wittamer V., Vassart G., Doms R.W., and Parmentier M. Multiple nonfunctional alleles of CCR5 are frequent in various human populations. Blood 96 (2000) 1638-1645
17. Bouma P., Leavitt M., Zhang P.F., Sidorov I.A., Dimitrov D.S., and Quinnan Jr. G.V. Multiple interactions across the surface of the gp120 core structure determine the global neutralization resistance phenotype of human immunodeficiency virus type 1. J. Virol. 77 (2003) 8061-8071
18. Bower J.F., Green T.D., and Ross T.M. DNA vaccines expressing soluble CD4-envelope proteins fused to C3d elicit cross-reactive neutralizing antibodies to HIV-1. Virology 328 (2004) 292-300
19. Bradney A.P., Scheer S., Crawford J.M., Buchbinder S.P., and Montefiori D.C. Neutralization escape in human immunodeficiency virus type 1-infected long-term nonprogressors. J. Infect. Dis. 179 (1999) 1264-1267
20. Broder C.C., and Dimitrov D.S. HIV and the 7-transmbembrane domain receptors. Pathobiology 64 (1996) 171-179
21. Brunel F.M., Zwick M.B., Cardoso R.M., Nelson J.D., Wilson I.A., Burton D.R., and Dawson P.E. Structure-function analysis of the epitope for 4E10, a broadly neutralizing human immunodeficiency virus type 1 antibody. J. Virol. 80 (2006) 1680-1687
22. Bullough P.A., Hughson F.M., Skehel J.J., and Wiley D.C. Structure of influenza haemagglutinin at the pH of membrane fusion. Nature 371 (1994) 37-43
23. Burton D.R. Antibodies, viruses and vaccines. Nat. Rev. Immunol. 2 (2002) 706-713
24. Burton D.R., and Montefiori D.C. The antibody response in HIV-1 infection. AIDS 11 Suppl. A (1997) S87-S98
25. Burton D.R., Pyati J., Koduri R., Sharp S.J., Thornton G.B., Parren P.W., Sawyer L.S., Hendry R.M., Dunlop N., Nara P.L., Lamacchia M., Garraty E., et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266 (1994) 1024-1027
26. Burton D.R., Desrosiers R.C., Doms R.W., Koff W.C., Kwong P.D., Moore J.P., Nabel G.J., Sodroski J., Wilson I.A., and Wyatt R.T. HIV vaccine design and the neutralizing antibody problem. Nat. Immunol. 5 (2004) 233-236
27. Burton D.R., Stanfield R.L., and Wilson I.A. Antibody vs. HIV in a clash of evolutionary titans. Proc. Natl. Acad. Sci. USA 102 (2005) 14943-14948
28. Cao Y., Qin L., Zhang L., Safrit J., and Ho D.D. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection [see comments]. N. Engl. J. Med. 332 (1995) 201-208
29. Cardoso R.M., Zwick M.B., Stanfield R.L., Kunert R., Binley J.M., Katinger H., Burton D.R., and Wilson I.A. Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity 22 (2005) 163-173
30. Carr C.M., and Kim P.S. A spring-loaded mechanism for the conformational changes of influenza hemagglutinin. Cell 73 (1993) 823-832
31. Cavacini L.A., Samore M.H., Gambertoglio J., Jackson B., Duval M., Wisnewski A., Hammer S., Koziel C., Trapnell C., and Posner M.R. Phase I study of a human monoclonal antibody directed against the CD4-binding site of HIV type 1 glycoprotein 120. AIDS Res. Hum. Retroviruses 14 (1998) 545-550
32. Cecilia D., Kleeberger C., Munoz A., Giorgi J.V., and Zolla-Pazner S. A longitudinal study of neutralizing antibodies and disease progression in HIV-1-infected subjects. J. Infect. Dis. 179 (1999) 1365-1374
33. Celada F., Cambiaggi C., Maccari J., Burastero S., Gregory T., Patzer E., Porter J., McDanal C., and Matthews T. Antibody raised against soluble CD4-rgp120 complex recognizes the CD4 moiety and blocks membrane fusion without inhibiting CD4-gp120 binding. J. Exp. Med. 172 (1990) 1143-1150
34. Center R.J., Lebowitz J., Leapman R.D., and Moss B. Promoting trimerization of soluble human immunodeficiency virus type 1 (HIV-1) Env through the use of HIV-1/simian immunodeficiency virus chimeras. J. Virol. 78 (2004) 2265-2276
35. Chackerian B., Rudensey L.M., and Overbaugh J. Specific N-linked and O-linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus variants that evolve in the host alter recognition by neutralizing antibodies. J. Virol. 71 (1997) 7719-7727
36. Chan D.C., and Kim P.S. HIV entry and its inhibition. Cell 93 (1998) 681-684
37. Chan D.C., Fass D., Berger J.M., and Kim P.S. Core structure of gp41 from the HIV envelope glycoprotein. Cell 89 (1997) 263-273
38. Cho M.W. Subunit protein vaccines: Theoretical and practical considerations for HIV-1. Curr. Mol. Med. 3 (2003) 243-263
39. Choe H., Li W., Wright P.L., Vasilieva N., Venturi M., Huang C.C., Grundner C., Dorfman T., Zwick M.B., Wang L., Rosenberg E.S., Kwong P.D., et al. Tyrosine sulfation of human antibodies contributes to recognition of the CCR5 binding region of HIV-1 gp120. Cell 114 (2003) 161-170
40. Choudhry V., Zhang M.Y., Dimitrova D., Prabakaran P., Dimitrov A.S., Fouts T.R., and Dimitrov D.S. Antibody-based inhibitors of HIV infection. Expert. Opin. Biol. Ther. 6 (2006) 523-531
41. Choudhry V., Zhang M.Y., Harris I., Sidorov I.A., Vu B., Dimitrov A.S., Fouts T., and Dimitrov D.S. Increased efficacy of HIV-1 neutralization by antibodies at low CCR5 surface concentration. Biochem. Biophys. Res. Commun. 348 (2006) 1107-1115
42. Coughlan C.M., McManus C.M., Sharron M., Gao Z., Murphy D., Jaffer S., Choe W., Chen W., Hesselgesser J., Gaylord H., Kalyuzhny A., Lee V.M., et al. Expression of multiple functional chemokine receptors and monocyte chemoattractant protein-1 in human neurons. Neuroscience 97 (2000) 591-600
43. D'Souza M.P., Allen M., Sheets R., and Johnston M.I. Current advances in HIV vaccines. Curr. HIV/AIDS Rep. 1 (2004) 18-24
44. Dalgleish A.G., Beverley P.C.L., Clapham P.R., Crawford D.H., Greaves M.F., and Weiss R.A. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 312 (1984) 763-767
45. Darbha R., Phogat S., Labrijn A.F., Shu Y., Gu Y., Andrykovitch M., Zhang M.Y., Pantophlet R., Martin L., Vita C., Burton D.R., Dimitrov D.S., et al. Crystal structure of the broadly cross-reactive HIV-1-neutralizing Fab X5 and fine mapping of its epitope. Biochemistry 43 (2004) 1410-1417
46. De C.E. Emerging anti-HIV drugs. Expert. Opin. Emerg. Drugs 10 (2005) 241-273
47. Decker J.M., Bibollet-Ruche F., Wei X., Wang S., Levy D.N., Wang W., Delaporte E., Peeters M., Derdeyn C.A., Allen S., Hunter E., Saag M.S., et al. Antigenic conservation and immunogenicity of the HIV coreceptor binding site. J. Exp. Med. 201 (2005) 1407-1419
48. Denisova G., Stern B., Raviv D., Zwickel J., Smorodinsky N.I., and Gershoni J.M. Humoral immune response to immunocomplexed HIV envelope glycoprotein 120. AIDS Res. Hum. Retroviruses 12 (1996) 901-909
49. Derdeyn C.A., Decker J.M., Bibollet-Ruche F., Mokili J.L., Muldoon M., Denham S.A., Heil M.L., Kasolo F., Musonda R., Hahn B.H., Shaw G.M., Korber B.T., et al. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 303 (2004) 2019-2022
50. Devico A., Silver A., Thronton A.M., Sarngadharan M.G., and Pal R. Covalently crosslinked complexes of human immunodeficiency virus type 1 (HIV-1) gp120 and CD4 receptor elicit a neutralizing immune response that includes antibodies selective for primary virus isolates. Virology 218 (1996) 258-263
51. DeVico A.L., Rahman R., Welch J., Crowley R., Lusso P., Sarngadharan M.G., and Pal R. Monoclonal antibodies raised against covalently crosslinked complexes of human immunodeficiency virus type 1 gp120 and CD4 receptor identify a novel complex-dependent epitope on gp 120. Virology 211 (1995) 583-588
52. Dimitrov A.S., Louis J.M., Bewley C.A., Clore G.M., and Blumenthal R. Conformational changes in HIV-1 gp41 in the course of HIV-1 envelope glycoprotein-mediated fusion and inactivation. Biochemistry 44 (2005) 12471-12479
53. Dimitrov D.S. Fusin-a place for HIV-1 and T4 cells to meet. Identifying the coreceptor mediating HIV-1 entry raises new hopes in the treatment of AIDS. Nat. Med. 2 (1996) 640-641
54. Dimitrov D.S. How do viruses enter cells? The HIV-1 coreceptors teach us a lesson of complexity. Cell 91 (1997) 721-730
55. Dimitrov D.S. Virus entry: Molecular mechanisms and biomedical applications. Nat. Rev. Microbiol. 2 (2004) 109-122
56. Dimitrov D.S., and Broder C.C. "HIV and Membrane Receptors." (1997), Landes Biosciences, Austin, TX
57. Dimitrov D.S., and Ji X. Crystal structure of a cross-reactive HIV-1 neutralizing CD4 binding site antibody Fab m14. Personal communication (2006)
58. Dimitrov D.S., Hillman K., Manischewitz J., Blumenthal R., and Golding H. Kinetics of soluble CD4 binding to cells expressing human immunodeficiency virus type 1 envelope glycoprotein. J. Virol. 66 (1992) 132-138
59. Dimitrov D.S., Xiao X., Chabot D.J., and Broder C.C. HIV coreceptors. J. Membr. Biol. 166 (1998) 75-90
60. Dix R.D., Pereira L., and Baringer J.R. Use of monoclonal antibody directed against herpes simplex virus glycoproteins to protect mice against acute virus-induced neurological disease. Infect. Immun. 34 (1981) 192-199
61. Doranz B.J., Lu Z.H., Rucker J., Zhang T.Y., Sharron M., Cen Y.H., Wang Z.X., Guo H.H., Du J.G., Accavitti M.A., Doms R.W., and Peiper S.C. Two distinct CCR5 domains can mediate coreceptor usage by human immunodeficiency virus type 1. J. Virol. 71 (1997) 6305-6314
62. Douek D.C., Kwong P.D., and Nabel G.J. The rational design of an AIDS vaccine. Cell 124 (2006) 677-681
63. Drakopoulou E., Vizzavona J., and Vita C. Engineering a CD4 mimetic inhibiting the binding of the human immunodeficiency virus-1 (HIV-1) envelope glycoprotein gp120 to human lymphocyte CD4 by the transfer of a CD4 functional site to a small natural scaffold. Lett. Pept. Sci. 5 (1998) 241-245
64. Duerr A., Wasserheit J.N., and Corey L. HIV vaccines: New frontiers in vaccine development. Clin. Infect. Dis. 43 (2006) 500-511
65. Eichberg J.W., Murthy K.K., Ward R.H., and Prince A.M. Prevention of HIV infection by passive immunization with HIVIg or CD4-IgG. AIDS Res. Hum. Retroviruses 8 (1992) 1515-1519
66. Emini E.A., Schleif W.A., Nunberg J.H., Conley A.J., Eda Y., Tokiyoshi S., Putney S.D., Matsushita S., Cobb K.E., and Jett C.M. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature 355 (1992) 728-730
67. Endres M.J., Clapham P.R., Marsh M., Ahuja M., Turner J.D., McKnight A., Thomas J.F., Stoebenau-Haggarty B., Choe S., Vance P.J., Wells T.N., Power C.A., et al. CD4-independent infection by HIV-2 is mediated by fusin/CXCR4. Cell 87 (1996) 745-756
68. Fass D., Harrison S.C., and Kim P.S. Retrovirus envelope domain at 1.7 angstrom resolution. Nat. Struct. Biol. 3 (1996) 465-469
69. Feng Y., Broder C.C., Kennedy P.E., and Berger E.A. HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272 (1996) 872-877
70. Ferrantelli F., Hofmann-Lehmann R., Rasmussen R.A., Wang T., Xu W., Li P.L., Montefiori D.C., Cavacini L.A., Katinger H., Stiegler G., Anderson D.C., McClure H.M., et al. Post-exposure prophylaxis with human monoclonal antibodies prevented SHIV89. 6P infection or disease in neonatal macaques. AIDS 17 (2003) 301-309
71. Ferrantelli F., Rasmussen R.A., Buckley K.A., Li P.L., Wang T., Montefiori D.C., Katinger H., Stiegler G., Anderson D.C., McClure H.M., and Ruprecht R.M. Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies. J. Infect. Dis. 189 (2004) 2167-2173
72. Forster F., Medalia O., Zauberman N., Baumeister W., and Fass D. Retrovirus envelope protein complex structure in situ studied by cryo-electron tomography. Proc. Natl. Acad. Sci. USA 102 (2005) 4729-4734
73. Forthal D.N., Landucci G., Haubrich R., Keenan B., Kuppermann B.D., Tilles J.G., and Kaplan J. Antibody-dependent cellular cytotoxicity independently predicts survival in severely immunocompromised human immunodeficiency virus-infected patients. J. Infect. Dis. 180 (1999) 1338-1341
74. Forthal D.N., Landucci G., and Keenan B. Relationship between antibody-dependent cellular cytotoxicity, plasma HIV type 1 RNA, and CD4+ lymphocyte count. AIDS Res. Hum. Retroviruses 17 (2001) 553-561
75. Fouts T., Godfrey K., Bobb K., Montefiori D., Hanson C.V., Kalyanaraman V.S., Devico A., and Pal R. Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques. Proc. Natl. Acad. Sci. USA 99 (2002) 11842-11847
76. Fouts T.R., Binley J.M., Trkola A., Robinson J.E., and Moore J.P. Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex. J. Virol. 71 (1997) 2779-2785
77. Fouts T.R., Tuskan R., Godfrey K., Reitz M., Hone D., Lewis G.K., and DeVico A.L. Expression and characterization of a single-chain polypeptide analogue of the human immunodeficiency virus type 1 gp120-CD4 receptor complex. J. Virol. 74 (2000) 11427-11436
78. Fox T.E., Finnegan C.M., Blumenthal R., and Kester M. The clinical potential of sphingolipid-based therapeutics. Cell. Mol. Life Sci. 63 (2006) 1017-1023
79. Freedman B.D., Liu Q.H., Del Corno M., and Collman R.G. HIV-1 gp120 chemokine receptor-mediated signaling in human macrophages. Immunol. Res. 27 (2003) 261-276
80. Gallaher W.R., Ball J.M., Garry R.F., Griffin M.C., and Montelaro R.C. A general model for the transmembrane proteins of HIV and other retroviruses. AIDS Res. Hum. Retroviruses 5 (1989) 431-440
81. Gallaher W.R., Ball J.M., Garry R.F., Martin-Amedee A.M., and Montelaro R.C. A general model for the surface glycoproteins of HIV and other retroviruses. AIDS Res. Hum. Retroviruses 11 (1995) 191-202
82. Gallo S.A., Finnegan C.M., Viard M., Raviv Y., Dimitrov A., Rawat S.S., Puri A., Durell S., and Blumenthal R. The HIV Env-mediated fusion reaction. Biochim. Biophys. Acta 1614 (2003) 36-50
83. Garber D.A., Silvestri G., and Feinberg M.B. Prospects for an AIDS vaccine: Three big questions, no easy answers. Lancet Infect. Dis. 4 (2004) 397-413
84. Gershoni J.M., Denisova G., Raviv D., Smorodinsky N.I., and Buyaner D. HIV binding to its receptor creates specific epitopes for the CD4/gp120 complex. FASEB J. 7 (1993) 1185-1187
85. Golding H., Zaitseva M., de Rosny E., King L.R., Manischewitz J., Sidorov I., Gorny M.K., Zolla-Pazner S., Dimitrov D.S., and Weiss C.D. Dissection of human immunodeficiency virus type 1 entry with neutralizing antibodies to gp41 fusion intermediates. J. Virol. 76 (2002) 6780-6790
86. Gomez-Roman V.R., Patterson L.J., Venzon D., Liewehr D., Aldrich K., Florese R., and Robert-Guroff M. Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251. J. Immunol. 174 (2005) 2185-2189
87. Gomez-Roman V.R., Florese R.H., Patterson L.J., Peng B., Venzon D., Aldrich K., and Robert-Guroff M. A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity. J. Immunol. Methods 308 (2006) 53-67
88. Gorny M.K., Conley A.J., Karwowska S., Buchbinder A., Xu J.Y., Emini E.A., Koenig S., and Zolla-Pazner S. Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody. J. Virol. 66 (1992) 7538-7542
89. Graham B.S. Clinical trials of HIV vaccines. Annu. Rev. Med. 53 (2002) 207-221
90. Gurtler L.G., Hauser P.H., Eberle J., von Brunn A., Knapp S., Zekeng L., Tsague J.M., and Kaptue L. A new subtype of human immunodeficiency virus type I (MVP-5180) from Cameroon. J. Virol. 68 (1994) 1581-1585
91. Harouse J.M., Bhat S., Spitalnik S.L., Laughlin M., Stefano K., Silberberg D.H., and Gonzalez-Scarano F. Inhibition of entry of HIV-1 in neural cell lines by antibodies against calactosyl ceramide. Science 253 (1991) 320-323
92. Haynes B.F., Fleming J., StClair W.E., Katinger H., Stiegler G., Kunert R., Robinson J., Scearce R.M., Plonk K., Staats H.F., Ortel T.L., Liao H.X., et al. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 308 (2005) 1096-1908
93. Haynes B.F., Moody M.A., Verkoczy L., Kelsoe G., and Alam S.M. Antibody polyspecificity and neutralization of HIV-1: A hypothesis. Hum. Antibodies 14 (2005) 59-67
94. He Y., D'Agostino P., and Pinter A. Analysis of the immunogenic properties of a single-chain polypeptide analogue of the HIV-1 gp120-CD4 complex in transgenic mice that produce human immunoglobulins. Vaccine 21 (2003) 4421-4429
95. Hesselgesser J., Halks-Miller M., DelVecchio V., Peiper S.C., Hoxie J., Kolson D.L., Taub D., and Horuk R. CD4-independent association between HIV-1 gp120 and CXCR4: Functional chemokine receptors are expressed in human neurons. Curr. Biol. 7 (1997) 112-121
96. Hioe C.E., Jones G.J., Rees A.D., Ratto-Kim S., Birx D., Munz C., Gorny M.K., Tuen M., and Zolla-Pazner S. Anti-CD4-binding domain antibodies complexed with HIV type 1 glycoprotein 120 inhibit CD4+ T cell-proliferative responses to glycoprotein 120. AIDS Res. Hum. Retroviruses 16 (2000) 893-905
97. Hioe C.E., Tuen M., Chien Jr. P.C., Jones G., Ratto-Kim S., Norris P.J., Moretto W.J., Nixon D.F., Gorny M.K., and Zolla-Pazner S. Inhibition of human immunodeficiency virus type 1 gp120 presentation to CD4 T cells by antibodies specific for the CD4 binding domain of gp120. J. Virol. 75 (2001) 10950-10957
98. Hoffman T.L., LaBranche C.C., Zhang W., Canziani G., Robinson J., Chaiken I., Hoxie J.A., and Doms R.W. Stable exposure of the coreceptor-binding site in a CD4-independent HIV-1 envelope protein. Proc. Natl. Acad. Sci. USA 96 (1999) 6359-6364
99. Hofmann-Lehmann R., Rasmussen R.A., Vlasak J., Smith B.A., Baba T.W., Liska V., Montefiori D.C., McClure H.M., Anderson D.C., Bernacky B.J., Rizvi T.A., Schmidt R., et al. Passive immunization against oral AIDS virus transmission: An approach to prevent mother-to-infant HIV-1 transmission?. J. Med. Primatol. 30 (2001) 190-196
100. Hofmann-Lehmann R., Vlasak J., Rasmussen R.A., Smith B.A., Baba T.W., Liska V., Ferrantelli F., Montefiori D.C., McClure H.M., Anderson D.C., Bernacky B.J., Rizvi T.A., et al. Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge. J. Virol. 75 (2001) 7470-7480
101. Hofmann-Lehmann R., Vlasak J., Rasmussen R.A., Jiang S., Li P.L., Baba T.W., Montefiori D.C., Bernacky B.J., Rizvi T.A., Schmidt R., Hill L.R., Keeling M.E., et al. Postnatal pre- and postexposure passive immunization strategies: Protection of neonatal macaques against oral simian-human immunodeficiency virus challenge. J. Med. Primatol. 31 (2002) 109-119
102. Holl V., Hemmerter S., Burrer R., Schmidt S., Bohbot A., Aubertin A.M., and Moog C. Involvement of Fc gamma RI (CD64) in the mechanism of HIV-1 inhibition by polyclonal IgG purified from infected patients in cultured monocyte-derived macrophages. J. Immunol. 173 (2004) 6274-6283
103. Holl V., Peressin M., Decoville T., Schmidt S., Zolla-Pazner S., Aubertin A.M., and Moog C. Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells. J. Virol. 80 (2006) 6177-6181
104. Holl V., Peressin M., Schmidt S., Decoville T., Zolla-Pazner S., Aubertin A.M., and Moog C. Efficient inhibition of HIV-1 replication in human immature monocyte-derived dendritic cells by purified anti-HIV-1 IgG without induction of maturation. Blood 107 (2006) 4466-4474
105. Huang C.C., Venturi M., Majeed S., Moore M.J., Phogat S., Zhang M.Y., Dimitrov D.S., Hendrickson W.A., Robinson J., Sodroski J., Wyatt R., Choe H., et al. Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120. Proc. Natl. Acad. Sci. USA 101 (2004) 2706-2711
106. Huang C.C., Stricher F., Martin L., Decker J.M., Majeed S., Barthe P., Hendrickson W.A., Robinson J., Roumestand C., Sodroski J., Wyatt R., Shaw G.M., et al. Scorpion-toxin mimics of CD4 in complex with human immunodeficiency virus gp120 crystal structures, molecular mimicry, and neutralization breadth. Structure (Camb.) 13 (2005) 755-768
107. Huang C.C., Tang M., Zhang M.Y., Majeed S., Montabana E., Stanfield R.L., Dimitrov D.S., Korber B., Sodroski J., Wilson I.A., Wyatt R., and Kwong P.D. Structure of a V3-containing HIV-1 gp120 core. Science 310 (2005) 1025-1028
108. Hunter E., and Swanstrom R. Retrovirus envelope glycoproteins. Curr. Top. Microbiol. Immunol. 157 (1990) 187-253
109. Hutto C., Zhou Y., He J., Geffin R., Hill M., Scott W., and Wood C. Longitudinal studies of viral sequence, viral phenotype, and immunologic parameters of human immunodeficiency virus type 1 infection in perinatally infected twins with discordant disease courses. J. Virol. 70 (1996) 3589-3598
110. Janssens W., Heyndrickx L., Fransen K., Motte J., Peeters M., Nkengasong J.N., Ndumbe P.M., Delaporte E., Perret J.L., Atende C., et al. Genetic and phylogenetic analysis of env subtypes G and H in central Africa. AIDS Res. Hum. Retroviruses 10 (1994) 877-879
111. Johnson W.E., and Desrosiers R.C. Viral persistance: HIV's strategies of immune system evasion. Annu. Rev. Med. 53 (2002) 499-518
112. Johnson W.E., Morgan J., Reitter J., Puffer B.A., Czajak S., Doms R.W., and Desrosiers R.C. A replication-competent, neutralization-sensitive variant of simian immunodeficiency virus lacking 100 amino acids of envelope. J. Virol. 76 (2002) 2075-2086
113. Johnson W.E., Lifson J.D., Lang S.M., Johnson R.P., and Desrosiers R.C. Importance of B-cell responses for immunological control of variant strains of simian immunodeficiency virus. J. Virol. 77 (2003) 375-381
114. Johnson W.E., Sanford H., Schwall L., Burton D.R., Parren P.W., Robinson J.E., and Desrosiers R.C. Assorted mutations in the envelope gene of simian immunodeficiency virus lead to loss of neutralization resistance against antibodies representing a broad spectrum of specificities. J. Virol. 77 (2003) 9993-10003
115. Kadow J., Wang H.G., and Lin P.F. Small-molecule HIV-1 gp120 inhibitors to prevent HIV-1 entry: An emerging opportunity for drug development. Curr. Opin. Investig. Drugs 7 (2006) 721-726
116. Kang C.Y., Hariharan K., Nara P.L., Sodroski J., and Moore J.P. Immunization with a soluble CD4-gp120 complex preferentially induces neutralizing anti-human immunodeficiency virus type 1 antibodies directed to conformation-dependent epitopes of gp120. J. Virol. 68 (1994) 5854-5862
117. Kensinger R.D., Yowler B.C., Benesi A.J., and Schengrund C.L. Synthesis of novel, multivalent glycodendrimers as ligands for HIV-1 gp120. Bioconjug. Chem. 15 (2004) 349-358
118. Kimata J.T., Gosink J.J., Kewalramani V.N., Rudensey L.M., Littman D.R., and Overbaugh J. Coreceptor specificity of temporal variants of simian immunodeficiency virus Mne. J. Virol. 73 (1999) 1655-1660
119. Kimata J.T., Kuller L., Anderson D.B., Dailey P., and Overbaugh J. Emerging cytopathic and antigenic simian immunodeficiency virus variants influence AIDS progression. Nat. Med. 5 (1999) 535-541
120. Klatzmann D., Champagne E., Chamaret S., Gruest J., Guetard D., Hercend T., Gluckman J.-C., and Montagnierce L. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature 312 (1984) 767-768
121. Kloosterboer N., Groeneveld P.H., Jansen C.A., van der Vorst T.J., Koning F., Winkel C.N., Duits A.J., Miedema F., van Baarle D., van Rij R.P., Brinkman K., and Schuitemaker H. Natural controlled HIV infection: Preserved HIV-specific immunity despite undetectable replication competent virus. Virology. 339 (2005) 70-80
122. Koch M., Pancera M., Kwong P.D., Kolchinsky P., Grundner C., Wang L., Hendrickson W.A., Sodroski J., and Wyatt R. Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition. Virology 313 (2003) 387-400
123. Koff W.C., Johnson P.R., Watkins D.I., Burton D.R., Lifson J.D., Hasenkrug K.J., McDermott A.B., Schultz A., Zamb T.J., Boyle R., and Desrosiers R.C. HIV vaccine design: Insights from live attenuated SIV vaccines. Nat. Immunol. 7 (2006) 19-23
124. Kolchinsky P., Kiprilov E., and Sodroski J. Increased neutralization sensitivity of CD4-independent human immunodeficiency virus variants. J. Virol. 75 (2001) 2041-2050
125. Korber B.T., Kunstman K.J., Patterson B.K., Furtado M., McEvilly M.M., Levy R., and Wolinsky S.M. Genetic differences between blood- and brain-derived viral sequences from human immunodeficiency virus type 1-infected patients: Evidence of conserved elements in the V3 region of the envelope protein of brain-derived sequences. J. Virol. 68 (1994) 7467-7481
126. Kwong P.D. Functional constraints and antibody recognition of the CD4-binding site on HIV-1 gp120. Fifth International Conference, AIDS Vaccine 06, 29 August-1 September 2006, Amsterdam, the Netherlands (2006)
127. Kwong P.D., Ryu S.-E., Henrickson W., Axel R., Sweet R., Folena-Wasserman G., and Hensley P. Molecular characteristics of recombinant human CD4 as deduced from polymorphic crystals. Proc. Natl. Acad. Sci. USA 87 (1990) 6423-6427
128. Kwong P.D., Wyatt R., Robinson J., Sweet R.W., Sodroski J., and Hendrickson W.A. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393 (1998) 648-659
129. Kwong P.D., Wyatt R., Majeed S., Robinson J., Sweet R.W., Sodroski J., and Hendrickson W.A. Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates. Structure 8 (2000) 1329-1339
130. Kwong P.D., Doyle M.L., Casper D.J., Cicala C., Leavitt S.A., Majeed S., Steenbeke T.D., Venturi M., Chaiken I., Fung M., Katinger H., Parren P.W., et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420 (2002) 678-682
131. Labrijn A.F., Poignard P., Raja A., Zwick M.B., Delgado K., Franti M., Binley J., Vivona V., Grundner C., Huang C.C., Venturi M., Petropoulos C.J., et al. Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J. Virol. 77 (2003) 10557-10565
132. Lange G., Lewis S.J., Murshudov G.N., Dodson G.G., Moody P.C., Turkenburg J.P., Barclay A.N., and Brady R.L. Crystal structure of an extracellular fragment of the rat CD4 receptor containing domains 3 and 4. Structure 2 (1994) 469-481
133. Lapham C.K., Ouyang J., Chandrasekhar B., Nguyen N.Y., Dimitrov D.S., and Golding H. Evidence for cell-surface association between fusin and the CD4-gp120 complex in human cell lines. Science 274 (1996) 602-605
134. Lapham C.K., Zaitseva M.B., Lee S., Romanstseva T., and Golding H. Fusion of monocytes and macrophages with HIV-1 correlates with biochemical properties of CXCR4 and CCR5. Nat. Med. 5 (1999) 303-308
135. Lefrancois L. Protection against lethal viral infection by neutralizing and nonneutralizing monoclonal antibodies: Distinct mechanisms of action in vivo. J. Virol. 51 (1984) 208-214
136. Leitner T., Alaeus A., Marquina S., Lilja E., Lidman K., and Albert J. Yet another subtype of HIV type 1?. AIDS Res. Hum. Retroviruses 11 (1995) 995-997
137. Letvin N.L. Progress toward an HIV vaccine. Annu. Rev. Med. 56 (2005) 213-223
138. Letvin N.L., Huang Y., Chakrabarti B.K., Xu L., Seaman M.S., Beaudry K., Korioth-Schmitz B., Yu F., Rohne D., Martin K.L., Miura A., Kong W.P., et al. Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys. J. Virol. 78 (2004) 7490-7497
139. Lian Y., Srivastava I., Gomez-Roman V.R., Zur Megede J., Sun Y., Kan E., Hilt S., Engelbrecht S., Himathongkham S., Luciw P.A., Otten G., Ulmer J.B., et al. Evaluation of envelope vaccines derived from the South African subtype C human immunodeficiency virus type 1 TV1 strain. J. Virol. 79 (2005) 13338-13349
140. Liao H.X., Alam S.M., Mascola J.R., Robinson J., Ma B., Montefiori D.C., Rhein M., Sutherland L.L., Scearce R., and Haynes B.F. Immunogenicity of constrained monoclonal antibody A32-human immunodeficiency virus (HIV) Env gp120 complexes compared to that of recombinant HIV type 1 gp120 envelope glycoproteins. J. Virol. 78 (2004) 5270-5278
141. Lin G., Baribaud F., Romano J., Doms R.W., and Hoxie J.A. Identification of gp120 binding sites on CXCR4 by using CD4-independent human immunodeficiency virus type 2 Env proteins. J. Virol. 77 (2003) 931-942
142. Littman D.R., Maddon P.J., and Axel R. Corrected CD4 sequence. Cell 55 (1988) 541
143. Liu S., and Jiang S. High throughput screening and characterization of HIV-1 entry inhibitors targeting gp41: Theories and techniques. Curr. Pharm. Des. 10 (2004) 1827-1843
144. Louwagie J., McCutchan F.E., Peeters M., Brennan T.P., Sanders-Buell E., Eddy G.A., Fransen G.G., van der K., Gershy-Damet G.M., Deleys R., et al. Phylogenetic analysis of gag genes from 70 international HIV-1 isolates provides evidence for multiple genotypes. AIDS 7 (1993) 769-780
145. Lu M., Blacklow S.C., and Kim P.S. A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat. Struct. Biol. 2 (1995) 1075-1082
146. Lu Z., Berson J.F., Chen Y., Turner J.D., Zhang T., Sharron M., Jenks M.H., Wang Z., Kim J., Rucker J., Hoxie J.A., Peiper S.C., et al.
147. Luciw P.A., Shaw K.E., Unger R.E., Planelles V., Stout M.W., Lackner J.E., Pratt-Lowe E., Leung N.J., Banapour B., and Marthas M.L. Genetic and biological comparisons of pathogenic and nonpathogenic molecular clones of simian immunodeficiency virus (SIVmac). AIDS Res. Hum. Retroviruses 8 (1992) 395-402
148. Luo M., Yuan F., Liu Y., Jiang S., Song X., Jiang P., Yin X., Ding M., and Deng H. Induction of neutralizing antibody against human immunodeficiency virus type 1 (HIV-1) by immunization with gp41 membrane-proximal external region (MPER) fused with porcine endogenous retrovirus (PERV) p15E fragment. Vaccine 24 (2006) 435-442
149. Maddon P., Littman D., Godfrey M., Maddon D., Chess L., and Axel R. The isolation and nucleotide sequence of a cDNA encoding the T cell surface protein T4: A new member of the immunoglobulin gene family. Cell 42 (1985) 93-104
150. Malashkevich V.N., Chan D.C., Chutkowski C.T., and Kim P.S. Crystal structure of the simian immunodeficiency virus (SIV) gp41 core: Conserved helical interactions underlie the broad inhibitory activity of gp41 peptides. Proc. Natl. Acad. Sci. USA 95 (1998) 9134-9139
151. Markosyan R.M., Cohen F.S., and Melikyan G.B. HIV-1 envelope proteins complete their folding into six-helix bundles immediately after fusion pore formation. Mol. Biol. Cell 14 (2003) 926-938
152. Markovic I. Advances in HIV-1 entry inhibitors: Strategies to interfere with receptor and coreceptor engagement. Curr. Pharm. Des. 12 (2006) 1105-1119
153. Markovic I., and Clouse K.A. Recent advances in understanding the molecular mechanisms of HIV-1 entry and fusion: Revisiting current targets and considering new options for therapeutic intervention. Curr. HIV Res. 2 (2004) 223-234
154. Martin L., Stricher F., Misse D., Sironi F., Pugniere M., Barthe P., Prado-Gotor R., Freulon I., Magne X., Roumestand C., Menez A., Lusso P., et al. Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes. Nat. Biotechnol. 21 (2003) 71-76
155. Martin L., Stricher F., Misse D., Sironi F., Pugniere M., Barthe P., Prado-Gotor R., Freulon I., Magne X., Roumestand C., Menez A., Lusso P., et al. Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes. Nat. Biotechnol. 21 (2003) 71-76
156. Mascola J.R., Lewis M.G., Stiegler G., Harris D., VanCott T.C., Hayes D., Louder M.K., Brown C.R., Sapan C.V., Frankel S.S., Lu Y., Robb M.L., et al. Protection of macaques against pathogenic simian/human immunodefiency virus 89. 6PD by passive transfer of neutralizing antibodies. J. Virol. 73 (1999) 4009-4018
157. Mascola J.R., Stiegler G., VanCott T.C., Katinger H., Carpenter C.B., Hanson C.E., Beary H., Hayes D., Frankel S.S., Birx D.L., and Lewis M.G. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6 (2000) 207-210
158. Mascola J.R., Lewis M.G., VanCott T.C., Stiegler G., Katinger H., Seaman M., Beaudry K., Barouch D.H., Korioth-Schmitz B., Krivulka G., Sambor A., Welcher B., et al. Cellular immunity elicited by human immunodeficiency virus type 1/simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies. J. Virol. 77 (2003) 10348-10356
159. Mascola J.R., Lewis M.G., VanCott T.C., Stiegler G., Katinger H., Seaman M., Beaudry K., Barouch D.H., Korioth-Schmitz B., Krivulka G., Sambor A., Welcher B., et al. Cellular immunity elicited by human immunodeficiency virus type 1/simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies. J. Virol. 77 (2003) 10348-10356
160. Mathews J.H., and Roehrig J.T. Determination of the protective epitopes on the glycoproteins of Venezuelan equine encephalomyelitis virus by passive transfer of monoclonal antibodies. J. Immunol. 129 (1982) 2763-2767
161. Mc Cann C.M., Song R.J., and Ruprecht R.M. Antibodies: Can they protect against HIV infection?. Curr. Drug Targets Infect. Disord. 5 (2005) 95-111
162. McMichael A.J. HIV vaccines. Annu. Rev. Immunol. 24 (2006) 227-255
163. Melikyan G.B., Markosyan R.M., Hemmati H., Delmedico M.K., Lambert D.M., and Cohen F.S. Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion. J. Cell Biol. 151 (2000) 413-423
164. Mitchison N.A., and Sattentau Q. Fundamental immunology and what it can teach us about HIV vaccine development. Curr. Drug Targets Infect. Disord. 5 (2005) 87-93
165. Montefiori D.C., Zhou I.Y., Barnes B., Lake D., Hersh E.M., Masuho Y., and Lefkowitz Jr. L.B. Homotypic antibody responses to fresh clinical isolates of human immunodeficiency virus. Virology 182 (1991) 635-643
166. Montefiori D.C., Pantaleo G., Fink L.M., Zhou J.T., Zhou J.Y., Bilska M., Miralles G.D., and Fauci A.S. Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors. J. Infect. Dis. 173 (1996) 60-67
167. Moore P.L., Crooks E.T., Porter L., Zhu P., Cayanan C.S., Grise H., Corcoran P., Zwick M.B., Franti M., Morris L., Roux K.H., Burton D.R., et al. Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J. Virol. 80 (2006) 2515-2528
168. Mori K., Yasutomi Y., Ohgimoto S., Nakasone T., Takamura S., Shioda T., and Nagai Y. Quintuple deglycosylation mutant of simian immunodeficiency virus SIVmac239 in rhesus macaques: Robust primary replication, tightly contained chronic infection, and elicitation of potent immunity against the parental wild-type strain. J. Virol. 75 (2001) 4023-4028
169. Moulard M., Phogat S.K., Shu Y., Labrijn A.F., Xiao X.D., Binley J.M., Zhang M.Y., Sidorov I.A., Broder C.C., Robinson J., Parren P.W.H.I., Burton D.R., et al. Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes. Proc. Natl. Acad. Sci. USA 99 (2002) 6913-6918
170. Muster T., Steindl F., Purtscher M., Trkola A., Klima A., Himmler G., Ruker F., and Katinger H. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 67 (1993) 6642-6647
171. Myers G., MacInnes K., and Korber B. The emergence of simian/human immunodeficiency viruses. AIDS Res. Hum. Retroviruses 8 (1992) 373-386
172. Myers G., Korber B., Wain-Hobson S., Jeang K.T., Henderson L.E., and Pavlakis G.N. "Human Retroviruses and AIDS: A Compilation and Analysis of Nucleic Acid and Amino Acid Sequences." (1994), Los Alamos National Laboratory, Los Alamos, NM
173. Nguyen M., Pean P., Lopalco L., Nouhin J., Phoung V., Ly N., Vermisse P., Henin Y., Barre-Sinoussi F., Burastero S.E., Reynes J.M., Carcelain G., et al. HIV-specific antibodies but not T-cell responses are associated with protection in seronegative partners of HIV-1-infected individuals in Cambodia. J. Acquir. Immune Defic. Syndr. 42 (2006) 412-419
174. Nishimura Y., Igarashi T., Haigwood N., Sadjadpour R., Plishka R.J., Buckler-White A., Shibata R., and Martin M.A. Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodies. J. Virol. 76 (2002) 2123-2130
175. Ofek G., Tang M., Sambor A., Katinger H., Mascola J.R., Wyatt R., and Kwong P.D. Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J. Virol. 78 (2004) 10724-10737
176. Pal R., Nair B.C., Hoke G.M., Sarngadharan M.G., and Edidin M. Lateral diffusion of CD4 on the surface of a human neoplastic T-cell line probed with a fluorescent derivative of the envelope glycoprotein (gp120) of human immunodeficiency virus type 1 (HIV-1). J. Cell. Physiol. 147 (1991) 326-332
177. Pancera M., Lebowitz J., Schon A., Zhu P., Freire E., Kwong P.D., Roux K.H., Sodroski J., and Wyatt R. Soluble mimetics of human immunodeficiency virus type 1 viral spikes produced by replacement of the native trimerization domain with a heterologous trimerization motif: Characterization and ligand binding analysis. J. Virol. 79 (2005) 9954-9969
178. Pantophlet R., Ollmann S.E., Poignard P., Parren P.W., Wilson I.A., and Burton D.R. Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120. J. Virol. 77 (2003) 642-658
179. Parren P.W., and Burton D.R. The antiviral activity of antibodies in vitro and in vivo. Adv. Immunol. 77 (2001) 195-262
180. Parren P.W., Moore J.P., Burton D.R., and Sattentau Q.J. The neutralizing antibody response to HIV-1: Viral evasion and escape from humoral immunity. AIDS 13 suppl. A (1999) S137-S162
181. Parren P.W.H.I., Marx P.A., Hessell A.J., Luckay A., Harouse J., Cheng-Mayer C., Moore J.P., and Burton D.R. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J. Virol. 75 (2001) 8340-8347
182. Pastori C., Weiser B., Barassi C., Uberti-Foppa C., Ghezzi S., Longhi R., Calori G., Burger H., Kemal K., Poli G., Lazzarin A., and Lopalco L. Long-lasting CCR5 internalization by antibodies in a subset of long-term nonprogressors: A possible protective effect against disease progression. Blood 107 (2006) 4825-4833
183. Picard L., Wilkinson D.A., McKnight A., Gray P.W., Hoxie J.A., Clapham P.R., and Weiss R.A. Role of the amino-terminal extracellular domain of CXCR-4 in human immunodeficiency virus type 1 entry. Virology 231 (1997) 105-111
184. Pierson T.C., and Doms R.W. HIV-1 entry and its inhibition. Curr. Top. Microbiol. Immunol. 281 (2003) 1-27
185. Pierson T.C., and Doms R.W. HIV-1 entry inhibitors: New targets, novel therapies. Immunol. Lett. 85 (2003) 113-118
186. Pilgrim A.K., Pantaleo G., Cohen O.J., Fink L.M., Zhou J.Y., Zhou J.T., Bolognesi D.P., Fauci A.S., and Montefiori D.C. Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. J. Infect. Dis. 176 (1997) 924-932
187. Platt E.J., Wehrly K., Kuhmann S.E., Chesebro B., and Kabat D. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J. Virol. 72 (1998) 2855-2864
188. Platt E.J., Durnin J.P., and Kabat D. Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus. J. Virol. 79 (2005) 4347-4356
189. Pleskoff O., Treboute C., and Alizon M. The cytomegalovirus-encoded chemokine receptor US28 can enhance cell-cell fusion mediated by different viral proteins. J. Virol. 72 (1998) 6389-6397
190. Poignard P., Saphire E.O., Parren P.W., and Burton D.R. Gp120: Biologic aspects of structural features. Annu. Rev. Immunol. 19 (2001) 253-274
191. Prabakaran P., Gan J., Feng Y., Zhu Z., Choudhry V., Xiao X., Ji X., and Dimitrov D.S. Structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody. J. Biol. Chem. 281 (2006) 15829-15836
192. Prabakaran P., Gan J., Wu Y.Q., Zhang M.Y., Dimitrov D.S., and Ji X. Structural mimicry of CD4 by a cross-reactive HIV-1 neutralizing antibody with CDR-H2 and H3 containing unique motifs. J. Mol. Biol. 357 (2006) 82-99
193. Puffer B.A., Sharron M., Coughlan C.M., Baribaud F., McManus C.M., Lee B., David J., Price K., Horuk R., Tsang M., and Doms R.W. Expression and coreceptor function of APJ for primate immunodeficiency viruses. Virology 276 (2000) 435-444
194. Puffer B.A., Pohlmann S., Edinger A.L., Carlin D., Sanchez M.D., Reitter J., Watry D.D., Fox H.S., Desrosiers R.C., and Doms R.W. CD4 independence of simian immunodeficiency virus Envs is associated with macrophage tropism, neutralization sensitivity, and attenuated pathogenicity. J. Virol. 76 (2002) 2595-2605
195. Putkonen P., Thorstensson R., Ghavamzadeh L., Albert J., Hild K., Biberfeld G., and Norrby E. Prevention of HIV-2 and SIVsm infection by passive immunization in cynomolgus monkeys. Nature 352 (1991) 436-438
196. Quinnan G.V., Zhang P.F., Fu D.W., Dong M., and Alter H.J. Expression and characterization of HIV type 1 envelope protein associated with a broadly reactive neutralizing antibody response. AIDS Res. Hum. Retroviruses 15 (1999) 561-570
197. Quinones-Kochs M.I., Buonocore L., and Rose J.K. Role of N-linked glycans in a human immunodeficiency virus envelope glycoprotein: Effects on protein function and the neutralizing antibody response. J. Virol. 76 (2002) 4199-4211
198. Rawat S.S., Viard M., Gallo S.A., Rein A., Blumenthal R., and Puri A. Modulation of entry of enveloped viruses by cholesterol and sphingolipids (Review). Mol. Membr. Biol. 20 (2003) 243-254
199. Ray N., and Doms R.W. HIV-1 coreceptors and their inhibitors. Curr. Top. Microbiol. Immunol. 303 (2006) 97-120
200. Reeves J.D., and Doms R.W. Human immunodeficiency virus type 2. J. Gen. Virol. 83 (2002) 1253-1265
201. Reinherz E.L., and Schlossmann S.F. The differentiation and function of human T lymphocytes. Cell 19 (1980) 821-827
202. Reinherz E.L., Kung P.C., Goldstein G., and Schlossmann S.F. Separation of functional subsets of human T cells by a monoclonal antibody. Proc. Natl. Acad. Sci. USA 76 (1979) 4061-4065
203. Reitter J.N., Means R.E., and Desrosiers R.C. A role for carbohydrates in immune evasion in AIDS. Nat. Med. 4 (1998) 679-684
204. Reitz Jr. M.S., Wilson C., Naugle C., Gallo R.C., and Robert-Guroff M. Generation of a neutralization-resistant variant of HIV-1 is due to selection for a point mutation in the envelope gene. Cell 54 (1988) 57-63
205. Richman D.D., Wrin T., Little S.J., and Petropoulos C.J. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl. Acad. Sci. USA 100 (2003) 4144-4149
206. Roben P., Moore J.P., Thali M., Sodroski J., Barbas III C.F., and Burton D.R. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J. Virol. 68 (1994) 4821-4828
207. Robinson J.E., Yoshiyama H., Holton D., Elliott S., and Ho D.D. Distinct antigenic sites on HIV gp120 identified by a panel of human monoclonal antibodies (abstr. Q449). J. Cell. Biochem. Suppl. 16E (1992) 71
208. Root M.J., and Steger H.K. HIV-1 gp41 as a target for viral entry inhibition. Curr. Pharm. Des. 10 (2004) 1805-1825
209. Rucker J., Samson M., Doranz B.J., Libert F., Berson J.F., Yi Y., Smyth R.J., Collman R.G., Broder C.C., Vassart G., Doms R.W., and Parmentier M. Regions in beta-chemokine receptors CCR5 and CCR2b that determine HIV-1 cofactor specificity. Cell 87 (1996) 437-446
210. Ruprecht R.M., Hofmann-Lehmann R., Smith-Franklin B.A., Rasmussen R.A., Liska V., Vlasak J., Xu W., Baba T.W., Chenine A.L., Cavacini L.A., Posner M.R., Katinger H., et al. Protection of neonatal macaques against experimental SHIV infection by human neutralizing monoclonal antibodies. Transfus. Clin. Biol. 8 (2001) 350-358
211. Ryu S.-E., Kwong P.D., Truneh A., Porter T.G., Arthos J., Rosenberg M., Dai X., Xuong N., Axel R., Sweet R.W., and Hendrickson W.A. Crystal structure of an HIV-binding recombinant fragment of human CD4. Nature 348 (1990) 419-426
212. Sanders R.W., Venturi M., Schiffner L., Kalyanaraman R., Katinger H., Lloyd K.O., Kwong P.D., and Moore J.P. The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J. Virol. 76 (2002) 7293-7305
213. Saphire E.O., Parren P.W., Pantophlet R., Zwick M.B., Morris G.M., Rudd P.M., Dwek R.A., Stanfield R.L., Burton D.R., and Wilson I.A. Crystal structure of a neutralizing human IGG against HIV-1: A template for vaccine design. Science 293 (2001) 1155-1159
214. Scanlan C.N., Pantophlet R., Wormald M.R., Ollmann S.E., Stanfield R., Wilson I.A., Katinger H., Dwek R.A., Rudd P.M., and Burton D.R. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120. J. Virol. 76 (2002) 7306-7321
215. Scarlatti G., Leitner T., Hodara V., Jansson M., Karlsson A., Wahlberg J., Rossi P., Uhlen M., Fenyo E.M., and Albert J. Interplay of HIV-1 phenotype and neutralizing antibody response in pathogenesis of AIDS. Immunol. Lett. 51 (1996) 23-28
216. Selvarajah S., Puffer B., Pantophlet R., Law M., Doms R.W., and Burton D.R. Comparing antigenicity and immunogenicity of engineered gp120. J. Virol. 79 (2005) 12148-12163
217. Sharma V.A., Kan E., Sun Y., Lian Y., Cisto J., Frasca V., Hilt S., Stamatatos L., Donnelly J.J., Ulmer J.B., Barnett S.W., and Srivastava I.K. Structural characteristics correlate with immune responses induced by HIV envelope glycoprotein vaccines. Virology 352 (2006) 131-144
218. Sharron M., Pohlmann S., Price K., Lolis E., Tsang M., Kirchhoff F., Doms R.W., and Lee B. Expression and coreceptor activity of STRL33/Bonzo on primary peripheral blood lymphocytes. Blood 96 (2000) 41-49
219. Shibata R., Igarashi T., Haigwood N., Buckler-White A., Ogert R., Ross W., Willey R., Cho M.W., and Martin M.A. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat. Med. 5 (1999) 204-210
220. Simon F., Mauclere P., Roques P., Loussert-Ajaka I., Muller-Trutwin M.C., Saragosti S., Georges-Courbot M.C., Barre-Sinoussi F., and Brun-Vezinet F. Identification of a new human immunodeficiency virus type 1 distinct from group M and group O. Nat. Med. 4 (1998) 1032-1037
221. Singh M., Jeang K.T., and Smith S.M. HIV vaccine development. Front. Biosci. 10 (2005) 2064-2081
222. Sloane A.J., Raso V., Dimitrov D.S., Xiao X., Deo S., Muljadi N., Restuccia D., Turville S., Kearney C., Broder C.C., Zoellner H., Cunningham A.L., et al. Marked structural and functional heterogeneity in CXCR4: Separation of HIV-1 and SDF-1alpha responses. Immunol. Cell Biol. 83 (2005) 129-143
223. Slobod K.S., Bonsignori M., Brown S.A., Zhan X., Stambas J., and Hurwitz J.L. HIV vaccines: Brief review and discussion of future directions. Expert Rev. Vaccines 4 (2005) 305-313
224. Smith A.E., and Helenius A. How viruses enter animal cells. Science 304 (2004) 237-242
225. Sodroski J.G. HIV-1 entry inhibitors in the side pocket. Cell 99 (1999) 243-246
226. Spearman P. Current progress in the development of HIV vaccines. Curr. Pharm. Des. 12 (2006) 1147-1167
227. Srivastava I.K., Stamatatos L., Legg H., Kan E., Fong A., Coates S.R., Leung L., Wininger M., Donnelly J.J., Ulmer J.B., and Barnett S.W. Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus. J. Virol. 76 (2002) 2835-2847
228. Srivastava I.K., Ulmer J.B., and Barnett S.W. Neutralizing antibody responses to HIV: Role in protective immunity and challenges for vaccine design. Expert Rev. Vaccines 3 (2004) S33-S52
229. Stanley J., Cooper S.J., and Griffin D.E. Monoclonal antibody cure and prophylaxis of lethal Sindbis virus encephalitis in mice. J. Virol. 58 (1986) 107-115
230. Starcich B.R., Hahn B.H., Shaw G.M., McNeely P.D., Modrow S., Wolf H., Parks E.S., Parks W.P., Josephs S.F., Gallo R.C., et al. Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS. Cell 45 (1986) 637-648
231. Staudinger R., Phogat S.K., Xiao X., Wang X., Dimitrov D.S., and Zolla-Pazner S. Evidence for CD4-enchanced signaling through the chemokine receptor CCR5. J. Biol. Chem. 278 (2003) 10389-10392
232. Stiegler G., Kunert R., Purtscher M., Wolbank S., Voglauer R., Steindl F., and Katinger H. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 17 (2001) 1757-1765
233. Subramaniam S. The SIV surface spike imaged by electron tomography: One leg or three?. PLoS Pathog. 2 8 (2006) e91
234. Suzuki S., Miyagi T., Chuang L.F., Yau P.M., Doi R.H., and Chuang R.Y. Chemokine receptor CCR5: Polymorphism at protein level. Biochem. Biophys. Res. Commun. 296 (2002) 477-483
235. Tian S., Choi W.T., Liu D., Pesavento J., Wang Y., An J., Sodroski J.G., and Huang Z. Distinct functional sites for human immunodeficiency virus type 1 and stromal cell-derived factor 1alpha on CXCR4 transmembrane helical domains. J. Virol. 79 (2005) 12667-12673
236. Trkola A., Dragic T., Arthos J., Binley J.M., Olson W.C., Allaway G.P., Cheng-Mayer C., Robinson J., Maddon P.J., and Moore J.P. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature 384 (1996) 184-187
237. Trkola A., Purtscher M., Muster T., Ballaun C., Buchacher A., Sullivan N., Srinivasan K., Sodroski J., Moore J.P., and Katinger H. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 70 (1996) 1100-1108
238. Tuen M., Visciano M.L., Chien Jr. P.C., Cohen S., Chen P.D., Robinson J., He Y., Pinter A., Gorny M.K., and Hioe C.E. Characterization of antibodies that inhibit HIV gp120 antigen processing and presentation. Eur. J. Immunol. 35 (2005) 2541-2551
239. Van Rompay K.K., Berardi C.J., Dillard T., Tarara R.P., Canfield D.R., Valverde C.R., Montefiori D.C., Cole K.S., Montelaro R.C., and Miller C.J. Passive immunization of newborn rhesus macaques prevents oral simian immunodeficiency virus infection. J. Infect. Dis. 177 (1998) 1247-1259
240. Varadarajan R., Sharma D., Chakraborty K., Patel M., Citron M., Sinha P., Yadav R., Rashid U., Kennedy S., Eckert D., Geleziunas R., Bramhill D., et al. Characterization of gp120 and its single-chain derivatives, gp120-CD4D12 and gp120-M9: Implications for targeting the CD4i epitope in human immunodeficiency virus vaccine design. J. Virol. 79 (2005) 1713-1723
241. Vita C., Drakopoulou E., Vizzavona J., Rochette S., Martin L., Menez A., Roumestand C., Yang Y.S., Ylisastigui L., Benjouad A., and Gluckman J.C. Rational engineering of a miniprotein that reproduces the core of the CD4 site interacting with HIV-1 envelope glycoprotein. Proc. Natl. Acad. Sci. USA 96 (1999) 13091-13096
242. Vita C., Drakopoulou E., Vizzavona J., Rochette S., Martin L., Menez A., Roumestand C., Yang Y.S., Ylisastigui L., Benjouad A., and Gluckman J.C. Rational engineering of a miniprotein that reproduces the core of the CD4 site interacting with HIV-1 envelope glycoprotein. Proc. Natl. Acad. Sci. USA 96 (1999) 13091-13096
243. Vujcic L.K., and Quinnan Jr. G.V. Preparation and characterization of human HIV type 1 neutralizing reference sera. AIDS Res. Hum. Retroviruses 11 (1995) 783-787
244. Wang J., Yan Y., Garrett T.P.J., Liu J., Rodgers D.W., Garlick R.L., Tarr G.E., Husain Y., Reinherz E.L., and Harrison S.C. Atomic structure of a fragment of human CD4 containing two immunoglobulin-like domains. Nature 348 (1990) 411-418
245. Wang L.X. Toward oligosaccharide- and glycopeptide-based HIV vaccines. Curr. Opin. Drug Discov. Devel. 9 (2006) 194-206
246. Watkins B.A., Reitz Jr. M.S., Wilson C.A., Aldrich K., Davis A.E., and Robert-Guroff M. Immune escape by human immunodeficiency virus type 1 from neutralizing antibodies: Evidence for multiple pathways. J. Virol. 67 (1993) 7493-7500
247. Wei X., Decker J.M., Wang S., Hui H., Kappes J.C., Wu X., Salazar-Gonzalez J.F., Salazar M.G., Kilby J.M., Saag M.S., Komarova N.L., Nowak M.A., et al. Antibody neutralization and escape by HIV-1. Nature 422 (2003) 307-312
248. Weiss C.D. HIV-1 gp41: Mediator of fusion and target for inhibition. AIDS Rev. 5 (2003) 214-221
249. Weissenhorn W., Dessen A., Harrison S.C., Skehel J.J., and Wiley D.C. Atomic structure of the ectodomain from HIV-1 gp41. Nature 387 (1997) 426-430
250. Wilkinson R.A., Piscitelli C., Teintze M., Cavacini L.A., Posner M.R., and Lawrence C.M. Structure of the Fab fragment of F105, a broadly reactive anti-human immunodeficiency virus (HIV) antibody that recognizes the CD4 binding site of HIV type 1 gp120. J. Virol. 79 (2005) 13060-13069
251. Williams A.F., Galfre G., and Milstein C. Analysis of cell surfaces by xenogeneic myeloma-hybrid antibodies: Differentiation antigens of rat lymphocytes. Cell 12 (1977) 663-673
252. Wu H., Kwong P.D., and Hendrickson W.A. Dimeric association and segmental variability in the structure of human CD4. Nature 387 (1997) 527-530
253. Wu L.J., Gerard N.P., Wyatt R., Choe H., Parolin C., Ruffing N., Borsetti A., Cardoso A.A., Desjardin E., Newman W., Gerard C., and Sodroski J. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature 384 (1996) 179-183
254. Wyatt R., and Sodroski J. The HIV-1 envelope glycoproteins: Fusogens, antigens, and immunogens. Science 280 (1998) 1884-1888
255. Wyatt R., Moore J., Accola M., Desjardin E., Robinson J., and Sodroski J. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. J. Virol. 69 (1995) 5723-5733
256. Xiang S.H., Doka N., Choudhary R.K., Sodroski J., and Robinson J.E. Characterization of CD4-induced epitopes on the HIV type 1 gp120 envelope glycoprotein recognized by neutralizing human monoclonal antibodies. AIDS Res. Hum. Retroviruses 18 (2002) 1207-1217
257. Xiang S.H., Kwong P.D., Gupta R., Rizzuto C.D., Casper D.J., Wyatt R., Wang L., Hendrickson W.A., Doyle M.L., and Sodroski J. Mutagenic stabilization and/or disruption of a CD4-bound state reveals distinct conformations of the human immunodeficiency virus type 1 gp120 envelope glycoprotein. J. Virol. 76 (2002) 9888-9899
258. Xiao X., Wu L., Stantchev T.S., Feng Y.R., Ugolini S., Chen H., Shen Z., Riley J.L., Broder C.C., Sattentau Q.J., and Dimitrov D.S. Constitutive cell surface association between CD4 and CCR5. Proc. Natl. Acad. Sci. USA 96 (1999) 7496-7501
259. Yang X., Farzan M., Wyatt R., and Sodroski J. Characterization of stable, soluble trimers containing complete ectodomains of human immunodeficiency virus type 1 envelope glycoproteins. J. Virol. 74 (2000) 5716-5725
260. Yang X., Lee J., Mahony E.M., Kwong P.D., Wyatt R., and Sodroski J. Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin. J. Virol. 76 (2002) 4634-4642
261. Yang X., Tomov V., Kurteva S., Wang L., Ren X., Gorny M.K., Zolla-Pazner S., and Sodroski J. Characterization of the outer domain of the gp120 glycoprotein from human immunodeficiency virus type 1. J. Virol. 78 (2004) 12975-12986
262. Zanetti G., Briggs J.A., Grunewald K., Sattentau Q.J., and Fuller S.D. Cryo-Electron Tomographic Structure of an Immunodeficiency Virus Envelope Complex in situ. PLoS Pathog. 2 8 (2006) e83
263. Zhang C.W., Chishti Y., Hussey R.E., and Reinherz E.L. Expression, purification, and characterization of recombinant HIV gp140. The gp41 ectodomain of HIV or simian immunodeficiency virus is sufficient to maintain the retroviral envelope glycoprotein as a trimer. J. Biol. Chem. 276 (2001) 39577-39585
264. Zhang L., Ribeiro R.M., Mascola J.R., Lewis M.G., Stiegler G., Katinger H., Perelson A.S., and Davenport M.P. Effects of antibody on viral kinetics in simian/human immunodeficiency virus infection: Implications for vaccination. J. Virol. 78 (2004) 5520-5522
265. Zhang M.Y., and Dimitrov D.S. Novel approaches for identification of broadly cross-reactive HIV-1 neutralizing human monoclonal antibodies and improvement of their potency. Curr. Pharm. Des. 13 (2007) 203-212
266. Zhang M.Y., Shu Y., Phogat S., Xiao X., Cham F., Bouma P., Choudhary A., Feng Y.R., Sanz I., Rybak S., Broder C.C., Quinnan G.V., et al. Broadly cross-reactive HIV neutralizing human monoclonal antibody Fab selected by sequential antigen panning of a phage display library. J. Immunol. Methods 283 (2003) 17-25
267. Zhang M.Y., Xiao X., Sidorov I.A., Choudhry V., Cham F., Zhang P.F., Bouma P., Zwick M., Choudhary A., Montefiori D.C., Broder C.C., Burton D.R., et al. Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody. J. Virol. 78 (2004) 9233-9242
268. Zhang M.Y., Choudhry V., Sidorov I.A., Tenev V., Vu B.K., Choudhary A., Lu H., Stiegler G.M., Katinger H.W.D., Jiang S., Broder C.C., and Dimitrov D.S. Selection of a novel gp41-specific HIV-1 neutralizing human antibody by competitive antigen panning. J. Immunol. Methods 317 (2006) 21-30
269. Zhang P.F., Bouma P., Park E.J., Margolick J.B., Robinson J.E., Zolla-Pazner S., Flora M.N., and Quinnan Jr. G.V. A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response. J. Virol. 76 (2002) 644-655
270. Zhang W., Canziani G., Plugariu C., Wyatt R., Sodroski J., Sweet R., Kwong P., Hendrickson W., and Chaiken I. Conformational changes of gp120 in epitopes near the CCR5 binding site are induced by CD4 and a CD4 miniprotein mimetic. Biochemistry 38 (1999) 9405-9416
271. Zhang Y.J., Fracasso C., Fiore J.R., Bjorndal A., Angarano G., Gringeri A., and Fenyo E.M. Augmented serum neutralizing activity against primary human immunodeficiency virus type 1 (HIV-1) isolates in two groups of HIV-1-infected long-term nonprogressors. J. Infect. Dis. 176 (1997) 1180-1187
272. Zhou T., Xu L., Dey B., Hessel A.J., Van Ryk D., Xiang S.H., Yang X., Zhang M.Y., Zwick M.B., Arthos J., Burton D.R., Dimitrov D.S., et al. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445 (2007) 732-737
273. Zhu P., Chertova E., Bess Jr. J., Lifson J.D., Arthur L.O., Liu J., Taylor K.A., and Roux K.H. Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immunodeficiency virus virions. Proc. Natl. Acad. Sci. USA 100 (2003) 15812-15817
274. Zhu P., Liu J., Bess Jr. J., Chertova E., Lifson J.D., Grise H., Ofek G.A., Taylor K.A., and Roux K.H. Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature 441 (2006) 847-852
275. Zolla-Pazner S. Identifying epitopes of HIV-1 that induce protective antibodies. Nat. Rev. Immunol. 4 (2004) 199-210
276. Zwick M.B. The membrane-proximal external region of HIV-1 gp41: A vaccine target worth exploring. AIDS 19 (2005) 1725-1737
277. Zwick M.B., Labrijn A.F., Wang M., Spenlehauer C., Saphire E.O., Binley J.M., Moore J.P., Stiegler G., Katinger H., Burton D.R., and Parren P.W. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J. Virol. 75 (2001) 10892-10905
278. Zwick M.B., Parren P.W., Saphire E.O., Church S., Wang M., Scott J.K., Dawson P.E., Wilson I.A., and Burton D.R. Molecular features of the broadly neutralizing immunoglobulin G1 b12 required for recognition of human immunodeficiency virus type 1 gp120. J. Virol. 77 (2003) 5863-5876